Calibrated real-time polymerase chain reaction for specific quantitation of HHV-6A and HHV-6B in clinical samplesGiulia Cassina, Mauro Malnati, Domenico Russo et al.|Journal of Virological Methods|2013Cited by 31
Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN studySilvia Nozza, Adriano Lazzarin, Laura Galli et al.|Clinical Microbiology and Infection|2014Cited by 26
Activating Killer Immunoglobulin Receptors and HLA-C: a successful combination providing HIV-1 controlMauro Malnati, Roberto Biassoni, Elisabetta Ugolotti et al.|Scientific Reports|2017Cited by 26
The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan–Deficient Muscular DystrophyElisabetta Gazzerro, Claudio Bruno, Serena Baratto et al.|American Journal Of Pathology|2018Cited by 18
Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trialMarco Ripa, Giuseppe Tambussi, Manuela Pogliaghi et al.|Clinical Microbiology and Infection|2015Cited by 14